Trials / Completed
CompletedNCT00525057
Dalteparin in Preventing DVT in Participants With Cancer
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
Detailed description
PRIMARY OBJECTIVES: I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT) in orthopedic oncology patients. II. To determine whether there are significantly increased bleeding complications at the surgical site after major oncologic operations in the lower extremity. OUTLINE: Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
Conditions
- Bone Sarcoma
- Femur Fracture
- Lymphoma
- Metastatic Neoplasm
- Pathologic Fracture
- Plasma Cell Myeloma
- Soft Tissue Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalteparin | Given SC |
Timeline
- Start date
- 2006-07-07
- Primary completion
- 2020-06-19
- Completion
- 2020-06-19
- First posted
- 2007-09-05
- Last updated
- 2021-01-22
- Results posted
- 2021-01-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00525057. Inclusion in this directory is not an endorsement.